The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis

References

• Barrett-ConnorE1992Hormone replacement and cancerBr Med Bull48345551450874
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorEGradyDSashegyiA2002Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year randomized trialJAMA2878475711851576
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDEnsrudK2000Upper gastrointestinal tract safety profile of alendronate. The Fracture Intervention TrialArch Intern Med1605172510695692
   PubMed Web of Science ®Google Scholar
• BenfordHLMC GowanNWHelfrichMH2001Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitroBone284657311344045
   PubMed Web of Science ®Google Scholar
• BjarnasonNHSarkarSDuongT2001Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosisOsteoporos Int129223011808544
   PubMed Web of Science ®Google Scholar
• BlackDCummingsSKarpfD1996Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet3481535418950879
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKE2003The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med34912071514500804
   PubMed Web of Science ®Google Scholar
• BoivinGMeunierPJ2003The mineralization of bone tissue: a forgotten dimension in osteoporosis researchOsteoporos Int3S192412730799
   PubMed Web of Science ®Google Scholar
• BoyceRWPaddockCLGleasonJR1995The effect of risedronate on canine cancellous bone remodeling: three dimensional kinetic reconstruction of the remodeling siteJ Bone Miner Res10211217754801
   PubMed Web of Science ®Google Scholar
• BryantHUGlasebrookALYangNN1995A pharmacological review of raloxifeneJ Bone Miner Metab1419
   Google Scholar
• BrzozowskiAMPikeACWDauterZ1997Molecular basis of agonism and antagonism in the oestrogen receptorNature38975389338790
   PubMed Web of Science ®Google Scholar
• BurgessTLQuianYKaufmanS1999The ligand for osteoprotegerin (OPGL) directly activates mature osteoclastsJ Cell Biol1455273810225954
   PubMed Web of Science ®Google Scholar
• CauleyJALucasFLKullerFH1996Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fracturesJAMA276140488892715
   PubMed Web of Science ®Google Scholar
• CauleyJANortonLLippmanME2001Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trialBreast Cancer Rest Treatment6512434
   Web of Science ®Google Scholar
• CenciSToraldoGWeitzmannMN2003Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivatorPNAS USA2104051012923292
   PubMed Web of Science ®Google Scholar
• ChesnutCHSkagAChristiansenC2004Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res191241915231010
   PubMed Web of Science ®Google Scholar
• ChesnutCHSilvermanSAndrianoK2000A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study GroupAm J Med1092677610996576
   PubMed Web of Science ®Google Scholar
• ColditzGAHankinsonSEHunterDJ1995The use of estrogens and progestins and the risk of breast cancer in postmenopausal womenN Engl J Med3321589937753136
   PubMed Web of Science ®Google Scholar
• CompstonJE1992HRT and osteoporosisBr Med Bull48309141450873
   PubMed Web of Science ®Google Scholar
• CosmanFNievesJWoelfertL2001Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawalJ Bone Miner Res169253111341338
   PubMed Web of Science ®Google Scholar
• CosmanFLindsayR2004Therapeutic potential of parathyroid hormoneCurr Osteoporos Rep251116036076
   PubMedGoogle Scholar
• CranneyAWellsGWillanA2002Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal womenEndocr Rev235081612202465
   PubMed Web of Science ®Google Scholar
• CummingsSREckertSKruegerKA1999The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene EvaluationJAMA28121899710376571
   PubMed Web of Science ®Google Scholar
• DecensiABonanniBGuerrieri-GonzagaA1998Biologic activity of tamoxifen at low doses in healthy womenJ Natl Cancer Inst90146179776411
   PubMed Web of Science ®Google Scholar
• DelmasPDBjarnasonNHMitlakBH1997Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med337164179385122
   PubMed Web of Science ®Google Scholar
• DelmasPDEnsrudKEAdachiJD2002Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab8736091712161484
   PubMed Web of Science ®Google Scholar
• Del PuenteAMigliaccioSEspositoA2004A reappraisal of therapeutic approaches to osteoporosisAging Clin Exp Res3S42S46
   Google Scholar
• DempsterDWCosmanFKurlandES2001Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy studyJ Bone Miner Res1618465311585349
   PubMed Web of Science ®Google Scholar
• Diez-PerezA2002BisphosphonatesMaturitas43SupplS19S2612361885
   PubMed Web of Science ®Google Scholar
• DufresneEChmielewskiPAManhartMD2003Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomographyCalcif Tissue Int734233212964065
   PubMed Web of Science ®Google Scholar
• EttingerBBlackDMMitlakBH1999Reduction of vertebral fracture risk in post menopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trialJAMA2826374510517716
   PubMed Web of Science ®Google Scholar
• EttingerBSan MartinJCransG2004Differential effects of teriparatide on BMD after treatment with raloxifene or alendronateJ Bone Miner Res197455115068497
   PubMed Web of Science ®Google Scholar
• EvansRM1988The steroid and thyroid hormone superfamilyScience240889953283939
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDL1998Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst901371889747868
   PubMed Web of Science ®Google Scholar
• TankóLBFelsenbergDCzerwiskiE2003Oral weekly ibandronate prevents bone loss in postmenopausal womenJ Intern Med2541596712859697
   PubMed Web of Science ®Google Scholar
• GandoliniGMigliaccioSBevilacquaM2004Prevent, treat and maintain: a new goal for osteoporosis management in clinical practiceAging Clin Exp Res3S37S41
   Google Scholar
• GianniWRicciAGazzanigaP2004Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical studyJ Clin Endocrinol Metab126097915579764
   PubMed Web of Science ®Google Scholar
• GoldDT2001The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomesRheum Dis Clin North Am272556211285999
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHK1999Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trialJAMA28213445210527181
   PubMed Web of Science ®Google Scholar
• HarringtonJTSte-MarieLGBrandiML2004Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosisCalcif Tissue Int741293514648009
   PubMed Web of Science ®Google Scholar
• HodsmanABBauerDCDempsterDW2005Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useEndocr Rev26688715769903
   PubMed Web of Science ®Google Scholar
• HofbauerLCKuhneCAViereckV2004The OPG/RANKL/RANK system in metabolic bone diseasesJ Musculoskelet Neuronal Interact42687515615494
   PubMedGoogle Scholar
• HughesDEDaiATiffeeJC1996Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-betaNat Med2113268837613
   PubMed Web of Science ®Google Scholar
• JensenEV1991Overview of the nuclear receptor familyParkerMGNuclear hormone receptors: molecular mechanisms, cellular functions, clinical abnormalitiesLondonAcad Pr113
   Google Scholar
• JilkaRLHangoeGGirasoleG1992Increased osteoclast development after estrogen loss: mediation by interleukin-6Science25788911621100
   PubMed Web of Science ®Google Scholar
• JuppnerHHeschRD1991Biochemical characterization of cellular hormone receptorsCurr Top Pathol8353691672514
   PubMedGoogle Scholar
• KadoDMBrownerWSPalermoL1999Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research GroupArch Intern Med15912152010371229
   PubMed Web of Science ®Google Scholar
• KaluDNLiuCCSalernoE1991Skeletal response of ovariectomized rats to low and high doses of 17 beta-estradiolJ Bone Miner Res1417587
   Web of Science ®Google Scholar
• KauffmanRFBryantHU1995Selective estrogen receptor modulatorsDrug News Perspect85318
   Google Scholar
• KeHZSimmonsHAPiriesCM1995Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized ratsEndocrinology1362435417750465
   PubMed Web of Science ®Google Scholar
• KlotzbuecherCMRossPDLandsmanPB2000Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res157213910780864
   PubMed Web of Science ®Google Scholar
• KumarRThompsonEB1999The structure of the nuclear hormone receptorsSteroids643101910406480
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBrollJ1995Effect of alendronate on BMD and the incidence of fractures in postmenopausal osteoporosisN Engl J Med3661213
   Google Scholar
• LindsayRHartDMAitkenJM1976Long-term prevention of post-menopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatmentLancet110384157448
   PubMed Web of Science ®Google Scholar
• LindsayRSilvermanSLCooperC2001Risk of new vertebral fracture in the year following a fractureJAMA285320311176842
   PubMed Web of Science ®Google Scholar
• MaYLBryantHUZengQ2003New bone formation with teriparatide [human parathyroid hormone-(1–34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized ratsEndocrinology14420081512697709
   PubMed Web of Science ®Google Scholar
• ManolagasC2000Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosisEndocr Rev211153710782361
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPD2001Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med3443334011172164
   PubMed Web of Science ®Google Scholar
• McClungMRWasnichRDReckerR2004Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosisJ Bone Miner Res19111814753731
   PubMed Web of Science ®Google Scholar
• McDonnellDPWijayaratneAChangC2002Elucidation of the molecular mechanism of action of selective estrogen receptor modulatorsAm J Cardiol90F35F43
   PubMed Web of Science ®Google Scholar
• MigliaccioSFalconeSSperaG2004Bone modeling and remodeling: from biology to clinical applicationAging Clin Exp Res3S20S22
   Google Scholar
• NeerRMArnaudCDZanchettaJR2001Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosisN Engl J Med34414344111346808
   PubMed Web of Science ®Google Scholar
• NickelsenTLifkinEGRiggsBL1999Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal womenPsychon euroendocrinology2411528
   PubMed Web of Science ®Google Scholar
• [NIH] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy2001Osteoporosis prevention, diagnosis, and therapyJAMA2857859511176917
   PubMed Web of Science ®Google Scholar
• NilssonSGustafssonJÅ2002Structure and function of the estrogen receptorManniAVerderameMFContemporary endocrinology: Selective estrogen receptor modulators: Research and clinical applicationsTotowa, NJHumana Pr318
   Google Scholar
• PacificiRBrownCPuscheckE1991Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cellsProc Natl Acad Sci USA88513482052592
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDA1999Multinational, placebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study GroupOsteoporos Int9461810550467
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJA1996Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol1478848558225
   PubMed Web of Science ®Google Scholar
• RaiszLG1993Local and systemic factors in the pathogenesis of osteoporosisWorld Rev Nutr Diet72921018506714
   PubMedGoogle Scholar
• RaiszLG2001Pathogenesis of postmenopausal osteoporosisRev Endocr Metab Disord251211704980
   PubMedGoogle Scholar
• RavnikarVA1992Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventative health benefits?Womens Health Issues275821617309
   PubMedGoogle Scholar
• ReginsterJYMinneHSorensenO2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosisOsteoporos Int11839110663363
   PubMed Web of Science ®Google Scholar
• ReginsterJY2005Ibandronate oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive reviewCurr Pharm Des1137112816305506
   PubMed Web of Science ®Google Scholar
• RehmanQLangTFArnaudCD2003Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosisOsteoporos Int14778112577188
   PubMed Web of Science ®Google Scholar
• ReszkaAARodanGA2004Nitrogen-containing bisphosphonate mechanism of actionMini Rev Med Chem47111915379639
   PubMed Web of Science ®Google Scholar
• RiggsBLHartmannLC2003Selective estrogen-receptor modulators—Mechanism of action and application to clinical practiceNew Engl J Med3486182912584371
   PubMed Web of Science ®Google Scholar
• RoschgerPRinnerthalerPYatesJ2001Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic womenBone291859111502482
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLKooperberC2002Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trialJAMA2883213312117397
   PubMed Web of Science ®Google Scholar
• RouxCSeemanEEastellR2004Efficacy of risedronate on clinical vertebral fractures within six monthsCurr Med Res Opin20433915119979
   PubMed Web of Science ®Google Scholar
• SahinerTAktanEKaleliB1998The effects of postmenopausal hormone replacement therapy on sympathetic skin responseMaturitas308589819788
   PubMed Web of Science ®Google Scholar
• SatoMRippyMKBryantHU1996Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized ratsFASEB J10905128666168
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiG2000Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)1211210746426
   PubMedGoogle Scholar
• SeemanEa. 2003Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosisOsteoporos Int14S2S812730770
   PubMed Web of Science ®Google Scholar
• SeemanEb. 2003Bone qualityOsteoporos Int14S5:37
   Web of Science ®Google Scholar
• SelyeH1932On the stimulation of new bone formation with parathyroid extract and irradiated ergosterolEndocrinology1654758
   Google Scholar
• ShortLLGlasebrookALAdrianMD1996Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferationJ Bone Miner Res1118770690
   PubMed Web of Science ®Google Scholar
• SorensenOHCrawfordGMMulderH2003Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone321202612633783
   PubMed Web of Science ®Google Scholar
• TarantaABramaMTetiA2002The selective estrogen receptor modulator Raloxifene modulates osteoblast and osteoclast activity in vitroBone3036537
   Web of Science ®Google Scholar
• TomasEKauppilaABlancoG1995Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patientsGynecol Oncol5926167590484
   PubMed Web of Science ®Google Scholar
• UsdinTBHiltonJVertesiT1999Distribution of the parathyroid hormone 2 receptor in rat: immunolocalization reveals expression by several endocrine cellsEndocrinology14033637110385434
   PubMed Web of Science ®Google Scholar
• VidalOKindblomLGOhlssonC1999Expression and localization of estrogen receptor-beta in murine and human boneJ Bone Miner Res14923910352100
   PubMed Web of Science ®Google Scholar
• WalshBWKullerLHWildRA1998Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal womenJAMA2791445519600478
   PubMed Web of Science ®Google Scholar
• [WHI] Writing Group for the Women’s Health Initiative Investigators2002Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women—Principal Results From the Women’s Health Initiative Randomized Controlled TrialJAMA2883213312117397
   PubMed Web of Science ®Google Scholar
• YaffeKKruegerKSarkarS2001Cognitive function in postmenopausal women treated with raloxifeneN Engl J Med34412071311309635
   PubMed Web of Science ®Google Scholar
• YangNNVenugopalanMHardikarS1996Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifeneScience273122258703055
   PubMed Web of Science ®Google Scholar
• YasudaHShimaNNakagawaN1998Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProc Natl Acad Sci USA9535976029520411
   PubMed Web of Science ®Google Scholar